Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China's NDRC Releases First Set Of Price Cuts; MNCs See Deepest Cuts As Expected

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's National Development and Reform Commission has released long-awaited price cuts that will mostly affect multinational pharma companies

You may also be interested in...



Asia Spotlight: GSK’s Lamictal, Sanofi’s Lantus Among Latest Round Of China Price Cuts

China’s NDRC cuts retail ceiling prices on more than 700 formulations of 400 drugs across 20 therapeutic areas, targeting newer products.

GSK’s Lamictal, Sanofi’s Lantus Among Latest Round Of China Price Cuts

China’s NDRC cuts retail ceiling prices on more than 700 formulations of 400 drugs across 20 therapeutic areas, targeting newer products.

Bristol’s Taxol, Sanofi’s Taxotere Among Latest Victims Of China Price Cuts

China’s NDRC cuts retail ceiling prices on 95 cancer, hematology and immunology drugs, with more cuts expected next year.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC073750

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel